{"id":46835,"date":"2022-08-02T16:01:42","date_gmt":"2022-08-02T14:01:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/"},"modified":"2022-08-02T16:01:42","modified_gmt":"2022-08-02T14:01:42","slug":"1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/","title":{"rendered":"$1.65 Bn RWE Oncology Markets by Component, Application, End User &#8211; Global Forecast to 2029 &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5632834\/rwe-oncology-market-by-component-application?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=xcrv6l&amp;utm_campaign=1733259+-+%241.65+Bn+RWE+Oncology+Markets+by+Component%2C+Application%2C+End+User+-+Global+Forecast+to+2029&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;RWE Oncology Market by Component, Application, End User &#8211; Global Forecast to 2029&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220802005759\/en\/1532006\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220802005759\/en\/1532006\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe RWE oncology solutions market is expected to grow at a CAGR of 14.2% from 2022-2029 to reach $1.65 billion by 2029.\n<\/p>\n<p>\nAfter a comprehensive primary and secondary research and an in-depth analysis of the market scenario, this report provides insights into key industry drivers, restraints, challenges, and opportunities of the RWE oncology solutions market.\n<\/p>\n<p>\nThe growth of this market is driven by factors such as the rising prevalence of cancer, rapidly growing big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare. Furthermore, emerging markets, rising focus on end-to-end RWE services, and rising adoption of mobile applications and wearable devices and AI in RWE are expected to provide significant growth opportunities for market players and new entrants in this market.\n<\/p>\n<p>\nBased on component, in 2022, the real-world datasets segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the growing amount of medical data generated in hospitals, increasing dependence on outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.\n<\/p>\n<p>\nBased on application, in 2022, the drug development &amp; approvals segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the rising number of cancer cases, compelling pharmaceutical and biopharmaceutical companies to focus on drug development for cancer treatment. The effective deployment of RWE can significantly accelerate the pace of discovery, enable drug approvals, and help understand the impact of new oncology therapies, boosting the growth of this segment.\n<\/p>\n<p>\nBased on end user, in 2022, the pharmaceutical &amp; medical device companies segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the importance of RWE studies in cancer drug development &amp; approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.\n<\/p>\n<p>\nIn 2022, North America is expected to command the largest share of the global RWE oncology solutions market, followed by Europe and Asia-Pacific.\n<\/p>\n<p>\n<strong>Market Insights<\/strong>\n<\/p>\n<p>\nDrivers\n<\/p>\n<ul>\n<li>\nGrowing Burden of Cancer\n<\/li>\n<li>\nRising Focus Towards Personalized Healthcare\n<\/li>\n<li>\nDelays in Drug Development and the Subsequent Increase in Development Costs\n<\/li>\n<li>\nShift Towards Value-based Care\n<\/li>\n<li>\nRapidly Growing Big Data in Healthcare\n<\/li>\n<\/ul>\n<p>\nRestraints\n<\/p>\n<ul>\n<li>\nReluctance to Rely on Real-world Studies\n<\/li>\n<\/ul>\n<p>\nOpportunities\n<\/p>\n<ul>\n<li>\nEmerging Economies\n<\/li>\n<li>\nRising Focus on End-to-end RWE Services\n<\/li>\n<li>\nRising Adoption of Wearable Devices, Mobile Apps, and Artificial Intelligence in RWE\n<\/li>\n<\/ul>\n<p>\nChallenges\n<\/p>\n<ul>\n<li>\nLack of Standardized Methodologies to Develop RWE\n<\/li>\n<li>\nImpact Assessment of COVID-19\n<\/li>\n<\/ul>\n<p>\nKey Market Trends\n<\/p>\n<ul>\n<li>\nGrowing Adoption of RWE in Drug Development and Commercialization\n<\/li>\n<li>\nRising Number of Consolidations\n<\/li>\n<li>\nImproved Patient Outcomes and value Creation from Real-world Evidence\n<\/li>\n<\/ul>\n<p>\n<strong>Company Profiles<\/strong>\n<\/p>\n<ul>\n<li>\nIQVIA Holdings Inc.\n<\/li>\n<li>\nICON plc\n<\/li>\n<li>\nPPD Inc.\n<\/li>\n<li>\nSYNEOS HEALTH Inc.\n<\/li>\n<li>\nCLARIVATE PLC\n<\/li>\n<li>\nMedpace Holdings Inc.\n<\/li>\n<li>\nSymphony Innovation LLC\n<\/li>\n<li>\nClinigen Group plc\n<\/li>\n<li>\nCognizant Technology Solutions Corporation\n<\/li>\n<li>\nOracle Corporation\n<\/li>\n<li>\nPAREXEL International Corporation\n<\/li>\n<li>\nPerkinElmer Inc.\n<\/li>\n<li>\nSAS Institute Inc.\n<\/li>\n<li>\nUnitedHealth Group Incorporated\n<\/li>\n<li>\nFlatiron Health\n<\/li>\n<\/ul>\n<p>\n<strong>Scope of the Report:<\/strong>\n<\/p>\n<p>\n<strong>RWE Oncology Solutions Market, by Component<\/strong>\n<\/p>\n<ul>\n<li>\nReal-world Datasets\n<\/li>\n<li>\nDisparate Datasets\n<\/li>\n<li>\nEMR\/EHR\/Clinical Data\n<\/li>\n<li>\nClaims &amp; Billing Data\n<\/li>\n<li>\nPharmacy Data\n<\/li>\n<li>\nCancer Registries\n<\/li>\n<li>\nOther Disparate Datasets\n<\/li>\n<li>\nIntegrated Datasets\n<\/li>\n<li>\nReal-world Consulting &amp; Analytics Services\n<\/li>\n<\/ul>\n<p>\n<strong>RWE Oncology Solutions Market, by Application<\/strong>\n<\/p>\n<ul>\n<li>\nDrug Development &amp; Approvals\n<\/li>\n<li>\nMarket Access &amp; Reimbursement\/Coverage Decisions\n<\/li>\n<li>\nPost-market Surveillance\n<\/li>\n<li>\nMedical Device Development &amp; Approvals\n<\/li>\n<li>\nOther Applications\n<\/li>\n<\/ul>\n<p>\n<strong>RWE Oncology Solutions Market, by End User<\/strong>\n<\/p>\n<ul>\n<li>\nPharmaceutical, Biotechnology, and Medical Device Companies\n<\/li>\n<li>\nHealthcare Payers\n<\/li>\n<li>\nHealthcare Providers\n<\/li>\n<li>\nOther End Users\n<\/li>\n<\/ul>\n<p>\n<strong>RWE Oncology Solutions Market, by Geography<\/strong>\n<\/p>\n<ul>\n<li>\nNorth America\n<\/li>\n<li>\nU.S.\n<\/li>\n<li>\nCanada\n<\/li>\n<li>\nEurope\n<\/li>\n<li>\nGermany\n<\/li>\n<li>\nFrance\n<\/li>\n<li>\nU.K.\n<\/li>\n<li>\nItaly\n<\/li>\n<li>\nSpain\n<\/li>\n<li>\nRest of Europe (RoE)\n<\/li>\n<li>\nAsia-Pacific (APAC)\n<\/li>\n<li>\nJapan\n<\/li>\n<li>\nChina\n<\/li>\n<li>\nIndia\n<\/li>\n<li>\nSouth Korea\n<\/li>\n<li>\nTaiwan\n<\/li>\n<li>\nSingapore\n<\/li>\n<li>\nRest of APAC (RoAPAC)\n<\/li>\n<li>\nLatin America\n<\/li>\n<li>\nMiddle East &amp; Africa\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5632834\/rwe-oncology-market-by-component-application?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=xcrv6l&amp;utm_campaign=1733259+-+%241.65+Bn+RWE+Oncology+Markets+by+Component%2C+Application%2C+End+User+-+Global+Forecast+to+2029&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/gy38t0<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;t&#111;&#58;&#x70;&#x72;e&#115;&#x73;&#x40;r&#101;&#115;&#x65;&#x61;r&#99;&#x68;&#x61;n&#100;&#109;&#x61;&#x72;k&#101;&#x74;&#x73;&#46;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">p&#114;&#x65;&#x73;&#x73;&#64;&#114;&#101;&#x73;&#x65;a&#114;&#99;&#x68;&#x61;nd&#109;&#x61;&#x72;&#x6b;e&#116;&#x73;&#x2e;&#x63;o&#109;<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;RWE Oncology Market by Component, Application, End User &#8211; Global Forecast to 2029&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The RWE oncology solutions market is expected to grow at a CAGR of 14.2% from 2022-2029 to reach $1.65 billion by 2029. After a comprehensive primary and secondary research and an in-depth analysis &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46835","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>$1.65 Bn RWE Oncology Markets by Component, Application, End User - Global Forecast to 2029 - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"$1.65 Bn RWE Oncology Markets by Component, Application, End User - Global Forecast to 2029 - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;RWE Oncology Market by Component, Application, End User &#8211; Global Forecast to 2029&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The RWE oncology solutions market is expected to grow at a CAGR of 14.2% from 2022-2029 to reach $1.65 billion by 2029. After a comprehensive primary and secondary research and an in-depth analysis ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-02T14:01:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220802005759\/en\/1532006\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"$1.65 Bn RWE Oncology Markets by Component, Application, End User &#8211; Global Forecast to 2029 &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-08-02T14:01:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\\\/\"},\"wordCount\":714,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220802005759\\\/en\\\/1532006\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\\\/\",\"name\":\"$1.65 Bn RWE Oncology Markets by Component, Application, End User - Global Forecast to 2029 - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220802005759\\\/en\\\/1532006\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-08-02T14:01:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220802005759\\\/en\\\/1532006\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220802005759\\\/en\\\/1532006\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"$1.65 Bn RWE Oncology Markets by Component, Application, End User &#8211; Global Forecast to 2029 &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"$1.65 Bn RWE Oncology Markets by Component, Application, End User - Global Forecast to 2029 - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"$1.65 Bn RWE Oncology Markets by Component, Application, End User - Global Forecast to 2029 - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;RWE Oncology Market by Component, Application, End User &#8211; Global Forecast to 2029&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The RWE oncology solutions market is expected to grow at a CAGR of 14.2% from 2022-2029 to reach $1.65 billion by 2029. After a comprehensive primary and secondary research and an in-depth analysis ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-02T14:01:42+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220802005759\/en\/1532006\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"$1.65 Bn RWE Oncology Markets by Component, Application, End User &#8211; Global Forecast to 2029 &#8211; ResearchAndMarkets.com","datePublished":"2022-08-02T14:01:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/"},"wordCount":714,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220802005759\/en\/1532006\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/","name":"$1.65 Bn RWE Oncology Markets by Component, Application, End User - Global Forecast to 2029 - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220802005759\/en\/1532006\/21\/logo.jpg","datePublished":"2022-08-02T14:01:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220802005759\/en\/1532006\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220802005759\/en\/1532006\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/1-65-bn-rwe-oncology-markets-by-component-application-end-user-global-forecast-to-2029-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"$1.65 Bn RWE Oncology Markets by Component, Application, End User &#8211; Global Forecast to 2029 &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46835"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46835\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}